TW202313010A - 治療粒線體相關病症之方法 - Google Patents

治療粒線體相關病症之方法 Download PDF

Info

Publication number
TW202313010A
TW202313010A TW111118998A TW111118998A TW202313010A TW 202313010 A TW202313010 A TW 202313010A TW 111118998 A TW111118998 A TW 111118998A TW 111118998 A TW111118998 A TW 111118998A TW 202313010 A TW202313010 A TW 202313010A
Authority
TW
Taiwan
Prior art keywords
subject
liver
methyl
disease
dinitrophenol
Prior art date
Application number
TW111118998A
Other languages
English (en)
Chinese (zh)
Inventor
沙哈雅 坎
黛安 喬卡斯基
Original Assignee
美商里維斯製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商里維斯製藥股份有限公司 filed Critical 美商里維斯製藥股份有限公司
Publication of TW202313010A publication Critical patent/TW202313010A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW111118998A 2021-05-20 2022-05-20 治療粒線體相關病症之方法 TW202313010A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163191321P 2021-05-20 2021-05-20
US63/191,321 2021-05-20
US202163222841P 2021-07-16 2021-07-16
US63/222,841 2021-07-16
US202263307515P 2022-02-07 2022-02-07
US63/307,515 2022-02-07

Publications (1)

Publication Number Publication Date
TW202313010A true TW202313010A (zh) 2023-04-01

Family

ID=82020295

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111118998A TW202313010A (zh) 2021-05-20 2022-05-20 治療粒線體相關病症之方法

Country Status (14)

Country Link
US (1) US20250177353A1 (https=)
EP (1) EP4340829A1 (https=)
JP (1) JP2024521709A (https=)
KR (1) KR20240021827A (https=)
AU (1) AU2022275935A1 (https=)
BR (1) BR112023024146A2 (https=)
CA (1) CA3219548A1 (https=)
CL (1) CL2023003441A1 (https=)
GE (1) GEAP202416398A (https=)
IL (1) IL308669A (https=)
JO (1) JOP20230298A1 (https=)
MX (1) MX2023013688A (https=)
TW (1) TW202313010A (https=)
WO (1) WO2022246039A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150759A1 (en) * 2022-02-07 2023-08-10 Rivus Pharmaceuticals, Inc. Methods of weight loss in a subject with elevated hba1c
TW202515545A (zh) * 2023-08-10 2025-04-16 大陸商深圳君聖泰生物技術有限公司 ２，４－二硝苯酚之衍生物以及前藥、以及其組成物以及方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1098641B1 (en) 1998-07-27 2016-04-27 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo

Also Published As

Publication number Publication date
EP4340829A1 (en) 2024-03-27
KR20240021827A (ko) 2024-02-19
JP2024521709A (ja) 2024-06-04
CL2023003441A1 (es) 2024-05-10
JOP20230298A1 (ar) 2023-11-19
US20250177353A1 (en) 2025-06-05
WO2022246039A1 (en) 2022-11-24
AU2022275935A1 (en) 2023-12-07
BR112023024146A2 (pt) 2024-01-30
CA3219548A1 (en) 2022-11-24
MX2023013688A (es) 2024-02-27
GEAP202416398A (en) 2024-01-25
IL308669A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
Zambrowicz et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes
JP2017526713A (ja) 線維症を処置するためのセニクリビロック併用療法
TW202214235A (zh) 用於治療先天性腎上腺增生之crf1受體拮抗劑
US20150157575A1 (en) Pharmaceutical Formulations Comprising Vilazodone
TW202313010A (zh) 治療粒線體相關病症之方法
JP2024523945A (ja) 血糖値の管理方法ならびに糖尿病及び関連状態の治療
KR20240162094A (ko) 미르다메티닙 치료
JP2024529452A (ja) 長時間作用型ｇｌｐ１／グルカゴン受容体アゴニストのための投薬レジメン
US20250262225A1 (en) Composition for treatment of covid-19 comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient
TW202114671A (zh) 包含fxr促效劑之治療
TW201215392A (en) Use of ranolazine for treating pulmonary hypertension
CN108042517A (zh) 用于治疗缺血性损伤的半胱胺和/或胱胺
US20250134864A1 (en) Methods of weight loss and preserving skeletal muscle mass
JP7794807B2 (ja) 気道疾患の治療に使用するための（１ｒ，３ｓ）－３－（（５－シアノ－４－フェニルチアゾール－２－イル）カルバモイル）シクロペンタン－１－カルボン酸およびその誘導体
CN111386115A (zh) 用于治疗非酒精性脂肪性肝炎的方法和药物组合物
US20210000792A1 (en) Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
US20250134865A1 (en) Methods of weight loss in a subject with elevated hba1c
CN117881399A (zh) 治疗粒线体相关病症的方法
WO2019099509A1 (en) Use of a p2x7 receptor antagonist to treat an inflammatory disease or disorder
CN118900692A (zh) HbA1c升高的受试者的体重减轻方法
CN118922187A (zh) 体重减轻和保持骨骼肌量的方法
US20260069588A1 (en) Vepdegestrant for use in treating cancer
TW202444359A (zh) 用於向患有肝損傷的患者施用帕妥索汀的組合物和方法
WO2026052001A1 (zh) Glp-1r激动剂与恩格列净的药物组合物及用途
JP2019513727A (ja) レンバチニブ及びエベロリムスを用いた腎細胞癌の治療